Can you use a GLP-1 and hormone therapy together in perimenopause?

Dr. Linda's take

If you are in perimenopause and already taking, or thinking about, a weight-management medication such as semaglutide, one question tends to come up again and again: is it okay to use it at the same time as hormone therapy? It is a fair thing to wonder, because these two treatments get discussed in completely separate corners of the internet, and almost no one explains how they sit together. My goal here is not to tell you what to take. It is to walk through what the drug labels actually say, what the early research suggests, and what that means for the conversation you have with your own clinician. This is general education, not advice for your specific situation.

What is perimenopause, and why does weight shift?

Perimenopause is the time leading up to menopause, the years when the ovaries gradually make less of the estrogen and progesterone hormones. That hormonal shift is associated with real changes in body composition: the menopause transition tends to bring an increase in fat mass and a decrease in lean body mass, even when eating and activity habits have not changed. Declining estrogen is also linked with more fat settling around the middle and with lower energy expenditure during the menopausal transition, which is part of why weight can creep up in these years despite no obvious change in routine.

I have written about the bigger midlife weight picture elsewhere, so I will keep this short and point you there rather than repeat it. If you are weighing your options, see our comparison of hormone therapy and these medications for midlife weight gain, and if you are worried about muscle while on one of these medications, see whether these medications cause muscle loss in perimenopause.

What is menopausal hormone therapy?

Menopausal hormone therapy, sometimes still called hormone replacement therapy or HRT, replaces some of the estrogen the body makes less of around menopause, and some regimens combine it with a second hormone. It is used mainly to ease menopause symptoms such as hot flashes and vaginal dryness, and it can be delivered as pills, skin patches, vaginal creams, gels, or rings. Whether hormone therapy is right for a given person is its own detailed decision, separate from anything to do with these medications.

Do the GLP-1 labels flag hormone therapy as a problem?

This is the part most people actually want answered. On the semaglutide (Wegovy) FDA label, hormone therapy is not listed as a contraindication. The label's contraindications are narrow: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide or its ingredients. Menopausal hormone therapy is not among them.

The label does describe one mechanism worth understanding. Semaglutide slows how quickly the stomach empties, and the prescribing information notes it therefore has the potential to impact the absorption of oral medications taken at the same time. For oral hormonal contraceptives specifically, the manufacturer's studies found no clinically relevant effect on their absorption, so the label does not restrict them. That gastric-emptying note is about oral absorption in general, not a specific warning against hormone therapy.

None of that means these medications and hormone therapy are automatically fine to combine for you. It means the label does not name hormone therapy as a contraindication or a formal drug interaction, which is a narrower and more specific statement than "safe."

What does the limited evidence say about using them together?

Direct research on using these medications and menopausal hormone therapy at the same time is still emerging, and most of it is small, retrospective, or short term. A 2026 review of this medication class in menopause gathered the early signals: across studies, these medications were associated with weight loss and a decrease in central adiposity in menopausal and postmenopausal women. Some preliminary findings in that review suggested that pairing hormone therapy with a GLP-1 may improve certain cardiometabolic markers, and one early result described greater body fat loss when hormone therapy was combined with a GLP-1 than with the GLP-1 alone. The same review is candid that this evidence rests largely on preclinical models and retrospective or short-term human studies, and that larger, more robust studies in menopausal women are still needed. In plain terms, there is no strong published signal of harm from combining them, but the evidence base for added benefit is still thin.

What should you ask your clinician?

If you want a structured way to start that conversation, Body Good Studio's quiz is built to map your symptoms to a starting point before you talk with a clinician.

Frequently asked questions

Is hormone therapy listed as a contraindication on the GLP-1 label?

No. On the semaglutide label, the contraindications are a personal or family history of medullary thyroid carcinoma or MEN 2, and a serious hypersensitivity reaction to the drug. Hormone therapy is not listed as a contraindication.

Can a GLP-1 keep my hormone therapy from working?

The semaglutide label notes that delayed stomach emptying has the potential to impact the absorption of oral medications generally, but the manufacturer's studies found no clinically relevant effect on oral contraceptive absorption. Whether that has any bearing on your specific hormone therapy is a question for your clinician.

Is it okay to take a GLP-1 and hormone therapy at the same time?

That is a decision only a licensed clinician who knows your full history can make. The label does not list hormone therapy as a contraindication, and early research has not flagged a clear danger, but the combined evidence is still limited, so this belongs in a real conversation with your prescriber.

Does hormone therapy make a GLP-1 work better or worse?

The research so far is preliminary and mixed. Some small studies suggest combining the two may improve certain cardiometabolic markers, while the overall evidence in menopausal women is still limited and short term. There is not yet enough high-quality data to say confidently either way.

Should I choose a GLP-1 or hormone therapy for menopausal weight gain?

They are built for different jobs, so it is not always one or the other. I compare the two in more detail in our comparison of hormone therapy and these medications for midlife weight gain.

References

1. MedlinePlus (2026). Menopause. National Library of Medicine. https://medlineplus.gov/menopause.html (Accessed 2026-07-15).
2. Simpson SJ, Raubenheimer D, Black KI, Conigrave AD (2023). Weight gain during the menopause transition: Evidence for a mechanism dependent on protein leverage. BJOG: An International Journal of Obstetrics and Gynaecology, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC10952331/ (Accessed 2026-07-15).
3. MedlinePlus (2026). Hormone Replacement Therapy. National Library of Medicine. https://medlineplus.gov/hormonereplacementtherapy.html (Accessed 2026-07-15).
4. U.S. Food and Drug Administration / Novo Nordisk (2025). WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 (Accessed 2026-07-15).
5. Graczyk NA, Bisschops J (2026). Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. Cureus, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC12908505/ (Accessed 2026-07-15).